Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials
{{output}}
SH-1028 is an irreversible third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Considering the possibility of combination therapy in patients with NSCLC, we investig... ...
